MaxCyte, Inc. (LON:MXCT – Get Free Report)’s share price hit a new 52-week low during trading on Thursday . The stock traded as low as GBX 200 ($2.60) and last traded at GBX 205.68 ($2.67), with a volume of 26796 shares trading hands. The stock had previously closed at GBX 213 ($2.77).
MaxCyte Trading Down 3.4 %
The business has a fifty day moving average price of GBX 294.19 and a two-hundred day moving average price of GBX 302.57. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The firm has a market capitalization of £271.51 million, a PE ratio of -7.54 and a beta of 1.13.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Recommended Stories
- Five stocks we like better than MaxCyte
- How to Choose Top Rated Stocks
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- 5 Top Rated Dividend Stocks to Consider
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
